pharma · Not applicable, healthy volunteers · ulcerative pyoderma gangrenosum
InflaRx
InflaRx GmbH
InflaRx is a pharma organization headquartered in Jena, DE. Primary therapeutic focus areas include Not applicable, healthy volunteers, ulcerative pyoderma gangrenosum. NovaPharmaNews links 4 clinical program(s), 0 drug
Company details
- Status
- Public
- HQ
- Jena, DE
- Founded
- 2007
- Employees
- 52
- Programs
- 4
- Drugs
- 20
- Patents
- 0
IFX-1-P3.4
Phase 3 · small molecule · ulcerative pyoderma gangrenosum
IFX-1-P3.4 for ulcerative pyoderma gangrenosum is a Phase 3 program (small_molecule) at InflaRx GmbH with 1 ClinicalTrials.gov record(s).
Internal code IFX-1-P3.4
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- InflaRx GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- ulcerative pyoderma gangrenosum
- Status
- active
- Trials
- 1